Literature DB >> 12610795

Bisphosphonates for arthritis--a confusing rationale.

Walter P Maksymowych.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12610795

Source DB:  PubMed          Journal:  J Rheumatol        ISSN： 0315-162X            Impact factor:   4.666


× No keyword cloud information.
  7 in total

1.  Spinal involvement in chronic recurrent multifocal osteomyelitis (CRMO) in childhood and effect of pamidronate.

Authors:  Toni Hospach; Micha Langendoerfer; Tekla von Kalle; Jan Maier; Guenther E Dannecker
Journal:  Eur J Pediatr       Date:  2010-03-27       Impact factor: 3.183

Review 2.  Late-onset ankylosing spondylitis and related spondylarthropathies: clinical and radiological characteristics and pharmacological treatment options.

Authors:  Eric Toussirot; Daniel Wendling
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 3.  New insights into synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome.

Authors:  Marina Magrey; Muhammad A Khan
Journal:  Curr Rheumatol Rep       Date:  2009-10       Impact factor: 4.592

4.  SAPHO Syndrome Diagnosis and Treatment: Report of Five Cases and Review of the Literature.

Authors:  Ch Matzaroglou; D Velissaris; A Karageorgos; M Marangos; E Panagiotopoulos; M Karanikolas
Journal:  Open Orthop J       Date:  2009-11-05

5.  Effects of zoledronic acid on physiologic bone remodeling of condylar part of TMJ: a radiologic and histomorphometric examination in rabbits.

Authors:  Ufuk Tatli; Yakup Ustün; Mehmet Kürkçü; Mehmet Emre Benlidayı
Journal:  ScientificWorldJournal       Date:  2014-01-21

6.  RANKL increases the level of Mcl-1 in osteoclasts and reduces bisphosphonate-induced osteoclast apoptosis in vitro.

Authors:  Karen A Sutherland; Helena L Rogers; Denise Tosh; Michael J Rogers
Journal:  Arthritis Res Ther       Date:  2009-04-30       Impact factor: 5.156

Review 7.  Emerging treatments for postmenopausal osteoporosis - focus on denosumab.

Authors:  Piet Geusens
Journal:  Clin Interv Aging       Date:  2009-06-09       Impact factor: 4.458
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.